JNJ - More Emergent BioSolutions produced COVID vaccines destroyed than previously reported

Contract vaccine manufacturer Emergent BioSolutions (NYSE:EBS) was forced to destroy 400M doses of COVID-19 vaccine due to contamination issues, a figure far higher than previously disclosed. In a report from the House Oversight and Reform Committee, a communication from an Emergent quality control employee to executives said that quality control issues at the company's Baltimore plant were not fully corrected even though batches of vaccine were being made. This was just prior to a September 2020 inspection by U.S. FDA officials. The quality issues at the Baltimore plant became national news due to the fact Emergent (EBS) was awarded a $628M federal contract, as well as separate contracts totaling $656M to produce COVID vaccines for Johnson & Johnson (JNJ) and AstraZeneca (AZN). Before the release of the report, Emergent (EBS) said 75M doses in total had to be discarded. The company suspended then resumed production of vaccines in July 2021. Yellow tags

For further details see:

More Emergent BioSolutions produced COVID vaccines destroyed than previously reported